Pharma company Mylan’s 3Q GAAP earnings of $0.36 per share declined 2.
Mylan has entered into an agreement to buy the rights to Aspen Pharmacare’s thrombosis business in Europe for EUR 641.9 million ($756.
After several postponed decisions, Mylan Inc (MYL) has announced that it is moving forward with a Botox biosimilar development program in collaboration with …
After a stock takes a tumble, wait just a minute before you count it out. While falling share prices could be a sign …
Investment banker Barclays announced it has initiated coverage of 20 U.S.
Analysts weigh in with confidence on two biotech stocks blasting through the roof this week.
Cantor cautiously welcomes MYL’s FDA success as EPS upside; Cowen applauds CTMX’s Probody technology.
Mylan N.V.
The biotech world is buzzing after a criminal charge-laden press release has circled the name of Valeant Pharmaceuticals Intl Inc (NYSE:VRX), Regeneron Pharmaceuticals …
Over the last several years there have been several instances of pharmaceutical companies increasing the price of its drugs by unfathomable proportions. The …
